Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback